Tislelizumab - BeiGene
Alternative Names: BGB-A317; TEVIMBRA; Tilelizumab; Tirelizumab - BeiGene; Tizveni; VDT-482Latest Information Update: 13 Jul 2024
At a glance
- Originator BeiGene
- Developer Asieris Pharmaceuticals; BeiGene; Celgene Corporation; HUTCHMED; Leap Therapeutics; Novartis; Tianjin Medical University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Registered Gastric cancer; Nasopharyngeal cancer
- Preregistration Oesophageal cancer; Small cell lung cancer
- Phase III Cancer
- Phase II Bladder cancer; Cervical cancer; Colorectal cancer; Lung cancer; Lymphoma; Rectal cancer
- Phase I/II Endometrial cancer; Haematological malignancies; Triple negative breast cancer
- No development reported Ovarian cancer; Renal cancer
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from phase II trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 BeiGene completes enrolment in a phase II trial for Colorectal cancer (Neo-adjuvant therapy) in China (IV) (NCT05116085)
- 31 May 2024 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)